Search

Introduction: Thyroid nodular goiter Nodular goiter is clinically recognizable restricted structure changes of the thyroid gland. Numerous studies show the relationship between thyroid autoimmunity and differentiated thyroid cancer in patients with nodular thyroid goiter. One of the important clinical marker in defining thyroid autoimmunity are antibodies to thyroid peroxidase. Objective: The aim of this study was to analyze the relationship between antibodies anti peroksidaznih ii thyroid malignancies in patients with thyroid altered thyroid. Material and Methods: We retrospectively reviewed the 248 reports of thyroid FNA cytology of samples obtained by puncture of patients with nodular thyroid goiter, at Department of thyroid gland, Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia in the period from October 2007. by January 2010. year. We analyzed the relationship between findings of cytopathological diagnostic categories and serum concentrations of anti peroxidase antibodies. The data were statistically processed using the computer program SPSS 12.0 software package. Results: Of total 248 patients, 148 patients (59.7%) had anti-TPO antibody values in a reference limits (30 IU/ml), and 40.3% elevated anti-TPO antibodies (over 30 IU/ml). In the group of patients with elevated values of anti-TPO antibodies 7% (7/100) of patients had malignant cytologic findings, and in the group of patients with anti-TPO antibody values in the normal range only 1.4% (2/148) of patients had malignant cytologic findings. Conclusion: Defining the relationship between thyroid autoimmune disease and differentiated thyroid cancer, providing new insights in the field of immunotherapy of thyroid carcinoma. Enlightening the molecular mechanisms link autoimmune thyroid disease and thyroid cancer development in patients with thyroid nodule help find new therapeutic strategies against thyroid cancer.

Introduction: Nodular goiter is clinically recognizable restricted structure changes of the thyroid gland. FNA is the first line diagnostic test for an enlarged thyroid gland. TSH is known as a thyroid growth factor, but the pathogenic role of this hormone in thyroid oncogenesis is unclear. Objective: The aim of this study is to analyze the relationship between elevated serum TSH concentartions and thyroid malignancies in patients with nodular thyroid goiter. Material and Methods: We retrospectively reviewed the 637 reports of thyroid FNA cytology of samples obtained by puncture of patients with nodular thyroid goiter, at Department of thyroid gland, Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia in the period from October 2007. by January 2010. year. We analyzed the relationship between findings of cytopathological diagnostic categories and serum concentrations of TSH. The data were statistically tested using Kruskal Wallis test of differences using the computer program SPSS 12.0 software package. Results: Of total 637 patients 3.45% (22/637) had a malignant, and 4.87% patients (31/637) cytopathological indeterminate findings. 91.52% (583/637) patients were with benign findings, and only one puncture failed. The average value of TSH in a group of patients with a diagnosis of malignancy was 9.83 ± 17.48 mmol/l with a median 3.31mmol/l. In all three diagnostic categories (benign, malignant and unspecified) most patients are with the normal concentrations of serum TSH , but there is a relatively large proportion of 27.3% (6/22) of patients with malignant cytopathological findings in the group of patients with elevated TSH concentartion. Statistically significant differences between diagnostic categories by group TSH values (χ²=8.136,p=0.017). Conclusion: It is concluded that the risk of developing thyroid malignancy increases in patients with elevated serum TSH concentrations. TSH should be used as an additional diagnostic tool in identifying high-risk patients who require further investigation and / or surgical treatment.

Introduction: Thyroid nodular goiter Nodular goiter is clinically recognizable restricted structure changes of the thyroid gland. Numerous studies show the relationship between thyroid autoimmunity and differentiated thyroid cancer in patients with nodular thyroid goiter. One of the important clinical markers in defining thyroid autoimmunity is an antibody to thyroid peroxidase. Objective: The aim of this study was to analyze the relationship between antibodies anti peroksidaznih ii thyroid malignancies in patients with thyroid-altered thyroid. Material and Methods: We retrospectively reviewed the 248 reports of thyroid FNA cytology of samples obtained by puncture of patients with nodular thyroid goiter, at Department of thyroid gland, Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia in the period from October 2007. by January 2010. year. We analyzed the relationship between findings of cytopathological diagnostic categories and serum concentrations of anti peroxidase antibodies. The data were statistically processed using the computer program SPSS 12.0 software package. Results: Of total 248 patients, 148 patients (59.7%) had anti-TPO antibody values in a reference limits (30 IU / ml), and 40.3% elevated anti-TPO antibodies (over 30 IU / ml). In the group of patients with elevated values of anti-TPO antibodies 7% (7/100) of patients had malignant cytologic findings, and in the group of patients with anti-TPO antibody values in the normal range only 1.4% (2/148) of patients had malignant cytologic findings. Conclusion: Defining the relationship between thyroid autoimmune disease and differentiated thyroid cancer, providing new insights in the field of immunotherapy of thyroid carcinoma. Enlightening the molecular mechanisms link autoimmune thyroid disease and thyroid cancer development in patients with thyroid nodule help find new therapeutic strategies against thyroid cancer. [ABSTRACT FROM AUTHOR]

Introduction: Thyroid nodular goiter Nodular goiter is clinically recognizable restricted structure changes of the thyroid gland. Numerous studies show the relationship between thyroid autoimmunity and differentiated thyroid cancer in patients with nodular thyroid goiter. One of the important clinical marker in defining thyroid autoimmunity are antibodies to thyroid peroxidase. Objective: The aim of this study was to analyze the relationship between antibodies anti peroksidaznih ii thyroid malignancies in patients with thyroid altered thyroid. Material and Methods: We retrospectively reviewed the 248 reports of thyroid FNA cytology of samples obtained by puncture of patients with nodular thyroid goiter, at Department of thyroid gland, Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia in the period from October 2007. by January 2010. year. We analyzed the relationship between findings of cytopathological diagnostic categories and serum concentrations of anti peroxidase antibodies. The data were statistically processed using the computer program SPSS 12.0 software package. Results: Of total 248 patients, 148 patients (59.7%) had anti-TPO antibody values in a reference limits (30 IU/ml), and 40.3% elevated anti-TPO antibodies (over 30 IU/ml). In the group of patients with elevated values of anti-TPO antibodies 7% (7/100) of patients had malignant cytologic findings, and in the group of patients with anti-TPO antibody values in the normal range only 1.4% (2/148) of patients had malignant cytologic findings. Conclusion: Defining the relationship between thyroid autoimmune disease and differentiated thyroid cancer, providing new insights in the field of immunotherapy of thyroid carcinoma. Enlightening the molecular mechanisms link autoimmune thyroid disease and thyroid cancer development in patients with thyroid nodule help find new therapeutic strategies against thyroid cancer. [ABSTRACT FROM AUTHOR]